Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa

Melanoma Research

Volumn 24, Issue 2, 2014, Pages 150-157

  Tarhini, Ahmad A ^a,b   Shin, Donghoon ^c   Lee, Sandra J ^c   Stuckert, Joseph ^b   Sander, Cindy A ^b   Kirkwood, John M ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Adjuvant; Autoimmunity; Interferon; Melanoma

Indexed keywords

ALPHA2B INTERFERON; AUTOANTIBODY; BIOLOGICAL MARKER; GANGLIOSIDE GM2; KEYHOLE LIMPET HEMOCYANIN; QS 21; ALPHA INTERFERON; CANCER VACCINE; HEMOCYANIN; KEYHOLE-LIMPET HEMOCYANIN;

ARTICLE; AUTOIMMUNE DISEASE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; ADJUVANT CHEMOTHERAPY; AUTOIMMUNITY; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; IMMUNOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; SKIN NEOPLASMS;

AUTOANTIBODIES; AUTOIMMUNITY; CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; G(M2) GANGLIOSIDE; HEMOCYANIN; HUMANS; INTERFERON-ALPHA; MELANOMA; PROGNOSIS; SKIN NEOPLASMS;

EID: 84896390403     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000050     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
3. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000; 18: 3782-3793.
4. Tarhini AA, Agarwala SS. Cutaneous melanoma: available therapy for metastatic disease. Dermatol The 2006; 19: 19-25.
5. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
6. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18: 2444-2458.
7. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370-2380.
8. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10: 1670-1677.
9. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
10. Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 2001; 19: 1430-1436.
11. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988; 318: 1557-1563.
12. Weijl NI, Van der Harst D, Brand A, Kooy Y, Van Luxemburg S, Schroder J, et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993; 11: 1376-1383.
13. Scalzo S, Gengaro A, Boccoli G, Masciulli R, Giannella G, Salvo G, et al. Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. Eur J Cancer 1990; 26: 1152-1156.
14. Krouse RS, Royal RE, Heywood G,Weintraub BD,White DE, Steinberg SM, et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol 1995; 18: 272-278.
15. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19: 3477-3482.
16. Becker JC, Winkler B, Klingert S, Brocker EB. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 1994; 73: 1621-1624.
17. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996; 19: 81-84.
18. Franzke A, Peest D, Probst-Kepper M, Buer J, Kirchner GI, Brabant G, et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 1999; 17: 529-533.
19. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372-8377.
20. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23: 741-750.
21. Dranoff G. CTLA-4 blockade: unveiling immune regulation. J Clin Oncol 2005; 23: 662-664.
22. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009; 27: 1075-1081.
23. Gogas H, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354: 709-718.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
25. Cox DR. Regression models and life tables (with discussion). J R Stat Soc B 1972; 34: 187-220.
26. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983; 9: 689-696.
27. Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 1987; 123: 1053-1055.
28. Schallreuter KU, Levenig C, Berger J. Vitiligo and cutaneous melanoma. A case study. Dermatologica 1991; 183: 239-245.
29. Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 2012; 30: 322-328.
30. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 2013; 8: e53745.
31. Deutsch M, Dourakis S, Manesis EK, Gioustozi A, Hess G, Horsch A, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology 1997; 26: 206-210.
32. Kalkner KM, Ronnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, Oberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. Qjm 1998; 91: 393-399.
33. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283-291.
34. Wesche B, Jaeckel E, Trautwein C,Wedemeyer H, Falorni A, Frank H, et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001; 48: 378-383.
35. Zuffa E, Vianelli N, Martinelli G, Tazzari P, Cavo M, Tura S. Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukemia. Haematologica 1996; 81: 533-535.
36. Vallisa D, Cavanna L, Berte R, Merli F, Ghisoni F, Buscarini L. Autoimmune thyroid dysfunctions in hematologic malignancies treated with alphainterferon. Acta Haematol 1995; 93: 31-35.
37. Satzger I, Meier A, Schenck F, Kapp A, Hauschild A, Gutzmer R. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer 2007; 121: 2562-2566.
38. Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, et al. Postsurgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366: 1189-1196.
39. Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol 2011; 12: 144-152.
40. Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 2009; 101: 869-877.
41. Bouwhuis MG, Suciu S, Testori A, Kruit WH, Sales F, Patel P, et al. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies - EORTC 18991. J Clin Oncol 2010; 28: 2460-2466.
42. Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008; 372: 117-126.
43. Gogas H, Kirkwood JM, Falk CS, Dafni U, Sondak VK, Tsoutsos D, et al. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer 2010; 116: 4326-4333.
44. Marincola FM, Venzon D, White D, Rubin JT, Lotze MT, Simonis TB, et al. HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res 1992; 52: 6561-6566.
45. Rubin JT, Day R, Duquesnoy R, Simonis B, Adams S, Lee J, et al. HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2. Ther Immunol 1995; 2: 1-6.
46. Scheibenbogen C, Keilholz U, Mytilineos J, Suciu S, Manasterski M, Hunstein W. HLA class I alleles and responsiveness of melanoma to immunotherapy with interferon-alpha (IFN-alpha) and interleukin-2 (IL-2). Melanoma Res 1994; 4: 191-194.
47. Gogas H, Kirkwood JM, Falk CS, Dafni U, Sondak VK, Tsoutsos D, et al. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer 2010; 116: 4326-4333.